View printer-friendly version
« Back
August 13, 2000 3:29 p.m.
Teva Received Marketing Approval for Copaxone® in the U.K.

The U.K. has agreed to act as a reference member state for the E.U wide registration

JERUSALEM, Israel, August 13, 2000 - Teva Pharmaceutical Industries, Ltd., (Nasdaq: TEVA) announced today that Copaxone® was approved for marketing in the U.K. This is the first approval in a major European market and enables Teva to file for approval all over the E.U. under the mutual recognition procedure.

Teva plans to launch Copaxone® in the U.K. market in the beginning of the fourth quarter of this year.

Copaxone® (glatiramer acetate for injection) is indicated for reduction in frequency of relapses in relapsing-remitting multiple sclerosis.

Eli Hurvitz, President and Chief Executive Officer commented: "We are excited to have received this approval and even more with the opportunity it represents for the rest of the European market".

Teva is currently preparing the filing under the European Mutual Recognition Procedure to make Copaxone® available in the remainder of the European Union. The U.K. has agreed to act as the reference member state. The successful completion of this procedure is expected to enable Teva to launch Copaxone® in the E.U. around mid 2001.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 50 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80% of its sales are outside Israel, mainly in North America and Europe. The Company develops, manufactures and markets generic and branded pharmaceuticals and active pharmaceutical ingredients.



Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, Teva's ability to rapidly integrate the operations of acquired businesses, the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration ("FDA") and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, exposure to product liability claims, dependence on patent and other protections for innovative products, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission ("SEC"). Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.